Current NICE/CDF drug approvals for CLL
NICE / CDF approvals for novel therapies in CLL as of October 2023 (England) |
|
Front-line |
Options |
No TP53 mutation or deletion |
FCR/BR unsuitable
FCR/BR suitable
|
TP53 mutated/deleted |
|
Lymphoid leukaemia – NICE Pathways
NICE / CDF approvals for novel therapies in CLL as of October 2023 (England) |
|
Relapse |
Options |
No TP53 mutation or deletion |
Prior Venetoclax and/or chemoimmunotherapy
Prior BTKi and/or chemoimmunotherapy
Prior BTKi and chemoimmunotherapy
|
TP53 mutated/deleted |
Prior BTKi therapy or if BTKi unsuitable
|
All patients for relapse < 24 months |
Idelalisib + Rituximab |
Lymphoid leukaemia – NICE Pathways
- NICE: National Institute of Clinical Excellence
- CDF: Cancer Drugs Fund
- FCR: Fludarabine, Cyclophosphamide, Rituximab
- BR: Bendamustine, Rituximab
- BTKi: Bruton’s Tyrosine Kinase inhibitor (Acalabrutinib, Ibrutinib)